User: prashantiyengar Topic: IP
Category: drugs :: india
Last updated: Mar 26 2015 16:38 IST RSS 2.0
 
1 to 20 of 2,554    
Stada agrees oncology deal with Indian Hetero Drugs 26.3.2015 Sify Finance
FRANKFURT (Reuters) - German generic drugmaker Stada struck an alliance with family-owned Hetero Drugs Ltd of India to gain access to active ingredients for cancer drugs, Stada said on Thursday.
Also found in: [+]
CAG slams Kerala Ayurveda company for laxity in manufacturing 26.3.2015 ET: Healthcare
The report also said the company admitted that it has the facility to test only microbial and physico-chemical parametres of products.
Also found in: [+]
SC stays HC order restraining firm from manufacturing anti-diabetes drugs 26.3.2015 TOI: India
The Supreme Court on Wednesday stayed a Delhi High Court order restraining Indian pharma company Glenmark Pharmaceuticals from manufacturing and selling its anti-diabetes drugs Zita and Zita-Met for allegedly infringing the patent rights of US drug major Merck Sharp and Dohme ...
Also found in: [+]
SC stays HC order against Glenmark in patent case 26.3.2015 TOI: India Business
The Supreme Court on Wednesday stayed a Delhi high court order restraining Glenmark Pharmaceuticals from manufacturing and selling its anti-diabetes drugs Zita and Zita-Met for allegedly infringing the patent rights of US drug major Merck Sharp and Dohme (MSD).
Also found in: [+]
Dilip Shanghvi's success: From a start-up to India's largest drug maker 11.3.2015 Rediff: Business
Dilip Shanghvi founded Sun Pharma in 1983.
Also found in: [+]
Germany's Boehringer loses India patent on lung drug to Cipla 10.3.2015 ET: Pharma
India's patent office ordered the revocation in a decision posted on its website on Thursday.
Also found in: [+]
Germany's Boehringer loses India patent on lung drug to Cipla 10.3.2015 Sify Finance
MUMBAI, March 10 (Reuters) - India has revoked a patent on German pharmaceutical company Boehringer Ingelheim's lung drug Spiriva and ruled in favour of domestic drugmaker Cipla Ltd , in the latest
Also found in: [+]
German firm Boehringer Ingelheim’s patent for asthma drug revoked 10.3.2015 ET: Pharma
India's Patent Office has revoked a patent on asthma drug, Spiriva held by German major Boehringer Ingelheim on an opposition filed by generic company, Cipla.
Also found in: [+]
Natco Pharma launches hepatitis C drug in Nepal 10.3.2015 ET: Pharma
The drug launched under the brand name Hepcinat is priced at Rs 19,900, or roughly $300 for 28 tablets, Natco said in its communication to the stock exchanges.
Also found in: [+]
German co’s patent for asthma drug revoked 10.3.2015 TOI: Home
India’s Patent Office has revoked a patent on asthma drug, Spiriva (tiotropium bromide monohydrate) held by German major Boehringer Ingelheim on an opposition filed by generic company, Cipla.
Also found in: [+]
Natco Pharma ties up with Gilead on hepatitis C drug 3.3.2015 TOI: India Business
Natco Pharma Ltd., the Indian drugmaker that had challenged Gilead Sciences Inc.'s patent claims on a blockbuster hepatitis C treatment in the Asian country, said it signed a licensing agreement with the US company for the drug.
Also found in: [+]
Natco Pharma ties up with Gilead Sciences for Hepatitis C drug 3.3.2015 ET: Healthcare
Natco was the only Indian generic drug maker that had filed a pre-grant patent opposition for the drug with the patent office.
Also found in: [+]
Obama Versus Obamacare: Acting at Big Pharma’s behest US president hurts India, others and his own legacy 12.2.2015 ET: Pharma
Latest negotiations with India – the leading source of generic drugs for developing countries – are a key part of this strategy.
Also found in: [+]
Big Pharma groupings urges US to ask India to change its IPR policies 12.2.2015 ET: Pharma
IPR issues, especially over drugs, have long been a sticky point in India-US bilateral relations which both countries are now trying to resolve.
Also found in: [+]
No question of 'appeasing' US or anyone else on IPR: Nirmala 9.2.2015 DNA: Top News
As the government readies its national IPR policy, Commerce and Industry Minister Nirmala Sitharaman said that there is no question of "appeasing" the US or anyone else. "Our IPR policy is in the making. The draft is out inviting inputs from all. No "trying to appease" anyone," she tweeted in reply to another tweet asking why India was trying to appease the US on Intellectual Property Rights (IPR). There are media reports that India is diluting its stand on issues such as data protection and patent linkage with the US. Recently, during the meeting of Sitharaman and US Commerce Secretary Penny Pritzker both the sides discussed IPR related issues. The minister invited comments from the US on the draft IPR policy, which was prepared with a six-member think tank. The US companies have alleged that India's IPR regime is discriminatory, particularly for pharmaceutical industry. But India has consistently maintained that its laws are compliant with global and WTO norms. The Commerce and Industry Ministry has ...
Also found in: [+]
Exports to reach Rs 1.1 lakh crore by FY'16 9.2.2015 ET: Foreign Trade
The pharmaceutical industry continues to benefit from lower cost of research and production which aids manufacturing for exports.
Also found in: [+]
Pharma exports to reach Rs 1.1 lakh crore by FY'16 9.2.2015 ET: Pharma
The pharmaceutical industry continues to benefit from lower cost of research and production which aids manufacturing for exports.
Also found in: [+]
HC asks patent office to review Gilead's case 3.2.2015 TOI: Cities
The Delhi high court has sent the decision of patent refusal for US firm Gilead's hepatitis C drug, Sovaldi, back to the patent office on procedural ...
Also found in: [+]
HC asks patent office to review Gilead’s case 3.2.2015 TOI: India Business
The Delhi high court has sent the decision of patent refusal for US firm Gilead’s hepatitis C drug, Sovaldi, back to the patent office on procedural grounds. The court’s decision is in response to Gilead’s writ petition seeking that the order rejecting its patent on the drug, be set aside.
Also found in: [+]
Patented drug price 30.1.2015 Telegraph: Nation
The drug price regulator has sought details of patented medicines as part of a drive to fix their rates.
Also found in: [+]
1 to 20 of 2,554